Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...
In a recent study posted to the bioRxiv* preprint server, researchers used various analytical characterization techniques to determine the biophysical attributes of the Imperial College London ...
In a recent study published in the journal PLOS Pathogens, researchers in the United States evaluated a novel self-amplifying replicon ribonucleic acid (RNA) vaccine against severe acute respiratory ...
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy ...
RNA is a central biological macromolecule, now widely harnessed in medicine and nanotechnology. Like proteins, RNA function often depends on its precise three-dimensional structure. A recent study ...
The new findings strengthen the "RNA world" hypothesis that describes how the first life on Earth could have used RNA instead ...
As the world continues to combat various infectious diseases, the development of novel vaccine technologies remains at the forefront of scientific research. mRNA-based vaccines and utilization of ...
The approval of messenger RNA (mRNA) based COVID-19 vaccines marked a pivotal scientific milestone, establishing mRNA as an innovative drug modality with immense therapeutic potential. However, due to ...
RNA viruses are renowned for their elegant structure and finely tuned self‐assembly processes, which are critical both for viral life cycles and for potential applications in nanotechnology and ...
Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback